MAGAOD

WHAT IS AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone (HGH), composed of amino acids 176–191 at the C-terminal end of the HGH molecule. Researchers discovered that this specific sequence is responsible for much of HGH’s fat-burning activity without its growth-promoting effects.

WHY IT WAS DEVELOPED

Developed by (Metabolic Pharmaceuticals Ltd), which is currently undergoing phase II clinical trials. AOD-9604 is a synthetic peptide based on a peptide derived from the Cterminus of the human growth hormone (GH).

It’s main mechanistic outcomes are

→ Targeted fat loss: Designed to promote lipolysis (fat breakdown) and inhibit lipogenesis (fat formation).

→ Safety advantage: Unlike HGH, AOD-9604 does not significantly impact IGF-1, insulin sensitivity, or blood sugar regulation 

→ Therapeutic potential: Initially investigated as an anti-obesity drug, it has since gained attention in the wellness and peptide therapy communities for weight loss and metabolic health. 

HOW AOD-9604 WORKS

AOD-9604 was designed to replicate the lipolytic (fat-burning) properties of human growth hormone while removing its growth and insulin-related activity. It acts primarily on fat metabolism pathways, making it highly specific compared to HGH.

MECHANISMS OF ACTION

→ Stimulates lipolysis: Enhances the breakdown of stored fat into free fatty acids, which can then be used for energy 

→ Inhibits lipogenesis: Suppresses the enzymes responsible for creating new fat tissue, reducing the body’s tendency to store excess energy as fat

→ Promotes fat oxidation: Encourages the body to burn fat as fuel, especially in combination with calorie control and exercise.

→ No IGF-1 or glucose disruption: Unlike HGH, AOD-9604 does not significantly increase IGF-1 or negatively affect insulin sensitivity, making it a safer candidate for metabolic regulation 

BENEFITS OF AOD-9604

When dosed consistently, AOD-9604 provides targeted fat-burning and metabolic support without the systemic hormonal risks seen with full-length HGH.

FAT LOSS AND BODY COMPOSITION

→ Accelerates fat breakdown: Stimulates lipolysis, helping release stored fatty acids for energy

→ Prevents fat storage: Inhibits lipogenesis, reducing the body’s ability to store new fat 

→ Targets abdominal/visceral fat: Clinical data suggests activity in reducing stubborn central fat, which is linked to metabolic risk.

METABOLIC HEALTH

→ Neutral on glucose control: Unlike HGH, AOD-9604 does not negatively impact insulin sensitivity or fasting blood glucose.

→ Improves lipid metabolism: Some evidence points to better cholesterol and triglyceride regulation in obese individuals.

JOINT AND RECOVERY BENEFITS

→ Cartilage regeneration: Early data suggests possible joint-protective properties, making it a potential therapeutic candidate for osteoarthritis and cartilage repair 

ADVANTAGES OVER OTHER FAT-LOSS THERAPIES

→ No IGF-1 elevation: Avoids risks of acromegaly or unwanted tissue growth.

→ Non-stimulant: Suitable for individuals sensitive to caffeine or thermogenics.

→ Safe profile: Clinical trials show AOD-9604 is well tolerated with a side-effect rate similar to placebo.

AOD-9604 DOSAGE PROTOCOLS

AOD-9604 is typically administered via subcutaneous injection, though compounded versions in capsules or troches also exist. In both clinical research and wellness settings, dosing is relatively consistent — low microgram amounts designed for daily use.

STANDARD CLINICAL DOSAGE

→ 200–500 mcg daily, delivered as a subcutaneous injection in the abdominal region.

→ Best administered in the morning, when fat mobilization is naturally higher.

→ Clinical trials investigating obesity used these dosing ranges with favorable safety outcomes 

EXPERIMENTAL / WELLNESS PROTOCOLS

→ 250–500 mcg daily, injected once per day, is the most common practice in weight loss clinics and peptide protocols.

→ Some practitioners recommend splitting the dose into two daily injections (AM + PM) to maintain steady exposure.

→ Often paired with diet and exercise regimens for enhanced fat-loss results.

ORAL AND TROCHE FORMS

→ Available through compounding pharmacies, but bioavailability is less consistent than injections.

→ Most effective results are seen with subcutaneous delivery due to direct absorption.

CYCLE LENGTH AND BEST PRACTICES

Since AOD-9604 is not a growth-promoting hormone and does not elevate IGF-1, its dosing protocols are generally designed for short to moderate cycles rather than continuous long-term use.

TYPICAL CYCLE LENGTHS

→ Weight loss protocols: 4–12 weeks, depending on goals and response.

→ Clinical trial durations: Most obesity studies used daily dosing for 12 weeks 

→ Wellness clinic use: Often structured in 8-week cycles, followed by reassessment before continuing.

BEST PRACTICES

→ Consistency matters: AOD-9604 is most effective when dosed daily without skipping, as its effects are gradual.

→ Stacking considerations: Can be combined with lifestyle interventions (calorie deficit, exercise) and, in some protocols, with other peptides such as CJC-1295/Ipamorelin for enhanced metabolic impact.

→ Injection site rotation: Rotate subcutaneous injection sites to reduce irritation.

→ Timing: Morning injections are preferred, aligning with natural circadian fat metabolism.

PRACTICAL TAKEAWAY

AOD-9604 should be approached as a supportive therapy — not a standalone fat-loss solution. Its best outcomes are achieved when paired with nutrition, training, and consistent cycle management

KEEP OUT OF REACH OF CHILDREN 

Should  BE STORED AT COLD TEMPERATURE 2-8•c (35-46•F)

PROTECT FROM SUNLIGHT

MANUFACTURED AND DISTRIBUTED BY:

MAGMA pharmaceuticals.Ltd